Mark Wildgust

1.1k total citations
19 papers, 588 citations indexed

About

Mark Wildgust is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Mark Wildgust has authored 19 papers receiving a total of 588 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 7 papers in Hematology. Recurrent topics in Mark Wildgust's work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Mark Wildgust is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Mark Wildgust collaborates with scholars based in United States, Germany and France. Mark Wildgust's co-authors include Alberto Gabizón, Olga Lyass, Gerald J. Berry, Andreas Hochhaus, Juan Luis Steegmann, Giuseppe Saglio, Concepción Boqué, Carolina Pavlovsky, Charles Chuah and Elias Jabbour and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Mark Wildgust

18 papers receiving 576 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Wildgust United States 8 352 350 185 179 156 19 588
G. Borthakur United States 11 482 1.4× 681 1.9× 127 0.7× 283 1.6× 43 0.3× 36 954
Н Д Хорошко Russia 8 651 1.8× 767 2.2× 126 0.7× 511 2.9× 43 0.3× 13 883
Laurie Letvak United States 14 566 1.6× 749 2.1× 144 0.8× 514 2.9× 64 0.4× 31 981
G. Rosti Italy 14 389 1.1× 436 1.2× 79 0.4× 295 1.6× 42 0.3× 24 555
Matthew J. Wong United States 8 185 0.5× 228 0.7× 130 0.7× 138 0.8× 52 0.3× 12 598
Stephanie R. Brockman United States 7 332 0.9× 265 0.8× 89 0.5× 430 2.4× 235 1.5× 8 844
Sarah Witt United States 5 130 0.4× 213 0.6× 135 0.7× 422 2.4× 55 0.4× 6 560
Feiyan Wang China 10 140 0.4× 139 0.4× 54 0.3× 44 0.2× 51 0.3× 28 400
Matteo Dell’Olio Italy 14 286 0.8× 83 0.2× 274 1.5× 17 0.1× 378 2.4× 30 624
Isabelle Desbois France 12 113 0.3× 203 0.6× 136 0.7× 15 0.1× 96 0.6× 26 415

Countries citing papers authored by Mark Wildgust

Since Specialization
Citations

This map shows the geographic impact of Mark Wildgust's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Wildgust with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Wildgust more than expected).

Fields of papers citing papers by Mark Wildgust

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Wildgust. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Wildgust. The network helps show where Mark Wildgust may publish in the future.

Co-authorship network of co-authors of Mark Wildgust

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Wildgust. A scholar is included among the top collaborators of Mark Wildgust based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Wildgust. Mark Wildgust is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Li, Wei, Jerome A. Feldman, Maxwell Sauder, et al.. (2025). 10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial. Journal of Thoracic Oncology. 20(3). S14–S16. 5 indexed citations
2.
Goldhammer, Hilary, et al.. (2025). A roadmap for engagement and inclusion of LGBTQIA+ people in clinical research. Nature Medicine. 31(3). 720–724. 1 indexed citations
3.
Feldman, Jerome A., Byoung Chul Cho, Nicolas Girard, et al.. (2025). Dermatologic prophylaxis and impact on patient-reported outcomes in first-line EGFR -mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial.. Journal of Clinical Oncology. 43(16_suppl). 8641–8641.
4.
Fonseca, Rafaël, Thierry Façon, Mahmoud Hashim, et al.. (2023). Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma. The Oncologist. 28(5). e263–e269. 16 indexed citations
5.
6.
Chowdhury, Simon, Paul N. Mainwaring, Liangcai Zhang, et al.. (2020). Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors. Frontiers in Oncology. 10. 1349–1349. 15 indexed citations
7.
Mainwaring, Paul N., et al.. (2019). Correlation of progression free survival-2 and overall survival in solid tumours. Annals of Oncology. 30. v184–v185. 3 indexed citations
8.
9.
Sorensen, Sonja, Mark Wildgust, Nishan Sengupta, et al.. (2017). Indirect Treatment Comparisons of Ibrutinib Versus Physician’s Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. Clinical Therapeutics. 39(1). 178–189.e5. 7 indexed citations
10.
Rule, Simon, Martin Dreyling, André Goy, et al.. (2017). Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open‐label studies. British Journal of Haematology. 179(3). 430–438. 90 indexed citations
11.
Rule, Simon, Martin Dreyling, Gregory P. Hess, et al.. (2016). Overall survival outcomes in patients with mantle-cell lymphoma (MCL) treated with Ibrutinib in a pooled analysis of 370 patients from 3 international open-label studies. Haematologica. 2 indexed citations
12.
Furman, Richard R., John N. Allan, Angela Howes, Michelle Mahler, & Mark Wildgust. (2016). Comparing overall survival (OS) outcomes in patients with newly diagnosed chronic lymphocytic leukemia (CLL) with normal life expectancy.. Journal of Clinical Oncology. 34(3_suppl). 7–7. 1 indexed citations
13.
14.
Martin, Peter, André Goy, Radhakrishnan Ramchandren, et al.. (2014). Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Blood. 124(21). 4461–4461. 2 indexed citations
15.
Jabbour, Elias, Hagop M. Kantarjian, Giuseppe Saglio, et al.. (2013). Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 123(4). 494–500. 301 indexed citations
16.
Saglio, Giuseppe, Hagop M. Kantarjian, Neil P. Shah, et al.. (2012). Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data. Blood. 120(21). 1675–1675. 27 indexed citations
17.
Gabizón, Alberto, Olga Lyass, Gerald J. Berry, & Mark Wildgust. (2004). Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil®/Caelyx®) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies. Cancer Investigation. 22(5). 663–669. 93 indexed citations
18.
Hussein, M. A., Mark Wildgust, John Fastenau, & Catherine Tak Piech. (2004). Cost effectiveness of DVd vs VAd in newly diagnosed multiple myeloma. Journal of Clinical Oncology. 22(14_suppl). 6548–6548. 2 indexed citations
19.
Hussein, M. A., Mark Wildgust, John Fastenau, & Catherine Tak Piech. (2004). Cost effectiveness of DVd vs VAd in newly diagnosed multiple myeloma. Journal of Clinical Oncology. 22(14_suppl). 6548–6548. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. Borthakur Breakdown of academic impact, for papers by Н Д Хорошко Breakdown of academic impact, for papers by Laurie Letvak Breakdown of academic impact, for papers by G. Rosti Breakdown of academic impact, for papers by Matthew J. Wong Breakdown of academic impact, for papers by Stephanie R. Brockman Breakdown of academic impact, for papers by Sarah Witt Breakdown of academic impact, for papers by Feiyan Wang Breakdown of academic impact, for papers by Matteo Dell’Olio Breakdown of academic impact, for papers by Isabelle Desbois
Rankless by CCL
2026